BRCA1 and cancer: The interim analysis of SOLO1 (NCT01844986) showed that BRCA1/2-mutated ovarian cancer patients could significantly benefit from Olaparib treatment (hazard ratio of cancer progression or patient death = 0.30, 95%CI 0.23–0.41, P < 0.001) [57].